For instance, the previous study from our team suggested peroxiredoxin 1 (PRDX1), and also PRDX2, as druggable targets in Burkitt lymphoma.8 Additionally, we have described PRDX1 to be a biomarker in breast cancer.9 This led us to a question whether targeting PRDX1 and/or PRDX2 could be a successful therapeutic strategy in this disease. Here, PRDX1 is linked to breast carcinoma.